Best mRNA / LNP CDMOs in Switzerland
· updated as new inspection, certificate, and trial data enters the platform
3
CDMOs tracked
2
Fully scored
2
With FDA records
3
FDA inspections
8
EMA/MHRA GMP certs
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 0 NAI (no action), 3 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (3), UNITED KINGDOM (3), Netherlands (2), Spain (1), SINGAPORE (1).
Last updated 2026-05-07. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 2 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| — |
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
|
Profiled | — | — | — | 0 programs |
What to evaluate in a mRNA / LNP CDMO
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Why are Swiss CDMOs positioned as premium-tier for biopharma manufacturing?
The Swiss CDMO cluster (Basel, Visp, Bern) hosts three attributes that reinforce a premium tier positioning: (1) regulatory alignment — Switzerland's Swissmedic runs a mutual-recognition GMP framework with the EU, so a Swiss facility supplying the EU doesn't need parallel EMA certification for the same activities; (2) technical depth — Swiss CDMOs have historically led on complex chemistry (Lonza on biologics + peptides, Bachem on peptides, CordenPharma on APIs) and on early-adopter viral vector manufacturing; (3) capital access — Swiss operations are able to make sustained capex investments in single-site scale-ups that lower-cost jurisdictions cannot match. That said, Swiss CDMOs also carry higher per-batch costs than Asian or Eastern European alternatives — the trade-off is process depth and regulatory posture, not price.
How does Switzerland's non-EU status affect drug supply to EU markets?
Switzerland is not an EU member state but maintains a bilateral Mutual Recognition Agreement (MRA) with the EU covering GMP inspections. Practically: a Swissmedic GMP inspection is recognized by EMA as equivalent to an EMA GMP inspection for the covered activity. Swiss-manufactured product does still require an EU-based Qualified Person for batch release into the EU market, but the facility itself does not need parallel EMA certification. This makes Swiss CDMOs operationally cleaner for pan-European supply than most non-EU alternatives. For UK supply, post-Brexit MHRA has continued to recognize the Swissmedic MRA under transitional arrangements — sponsors supplying both EU and UK should confirm current MHRA policy at RFP stage.
Which Swiss CDMOs are also present in the US and Asia?
The largest Swiss CDMOs — Lonza, CordenPharma, Bachem — operate global site networks spanning Switzerland, US, and (in Lonza's case) multiple Asian geographies. This multi-region posture materially reduces regulatory tech-transfer risk for programs supplying multiple markets from a single CDMO relationship. Cross-check with the US region ranking and Asia region ranking to identify Swiss-headquartered CDMOs with cross-jurisdictional footprint. Individual profile pages surface the specific site network.
mRNA / LNP CDMOs — Frequently Asked Questions
Who are the top mRNA / LNP CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include Lonza, Lonza Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 2 mRNA / LNP CDMOs with FDA inspection records and 8 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Related modalities